Ipriflavone (Osteofix)

Catalog No.S2422 Batch:S242201

Print

Technical Data

Formula

C18H16O3
Molecular Weight 280.32 CAS No. 35212-22-7
Solubility (25°C)* In vitro DMSO 56 mg/mL (199.77 mM)
Ethanol 2 mg/mL (7.13 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.
Targets
advanced glycation end products (AGE) [2]
In vitro Ipriflavone regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of some important matrix proteins and facilitating the mineralization process. [1] Ipriflavone treatment at 10 μM significantly inhibits advanced glycation end products (AGE) enhanced bone resorption in cultured mouse unfractionated bone cells. [2] In addition, Ipriflavone treatment potently enhances calcium uptake by duodenal cells. [3] Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells in a dose-dependent manner, and blocks the ligand-induced phosphorylation of Tyr845 of the EGFR. Ipriflavone treatment at 50 μM does not induce apoptosis of MDA-231 cells. [4]
In vivo Oral administration of Ipriflavone at 12 mg but not 6 mg significantly inhibits the development of new osteolytic bone metastases of MDA-231 cells, suppresses the progression of established osteolytic lesions, and reduces the number of osteoclasts adjacent to cancer cells in bone metastases. Consistent with the in vitro activity, Ipriflavone treatment at 6 or 12 mg/day significantly inhibits tumor growth of MDA-231 xenografts with 25% and 45% reductions by volume and 47% and 63% by weight, respectively, compared to untreated mice, and prolongs the life of tumor-bearing mice. [4] LD50: Mice >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.); Rats >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.) [5]

Protocol (from reference)

Cell Assay:[4]
  • Cell lines

    MDA-231 cells

  • Concentrations

    Dissolved in absolute ethanol, final concentrations ~50 μM

  • Incubation Time

    24, 48, 72 and 96 hours

  • Method

    Cells are exposed to various concentrations of Ipriflavone for 24, 48, 72 and 96 hours. Cells are treated with trypan blue to estimate the number of viable cells. For thymidine incorporation analysis, [3H]Thymidine (1 μCi) is added, and cells are harvested onto glass fiber filters 4 hours later. Radioactivity is determined by scintillation counting.
Animal Study:[4]
  • Animal Models

    Male athymic nude mice (ICR-nu/nu) injected s.c. or intracardially with MDA-231 human breast cancer cells

  • Dosages

    ~12 mg/day

  • Administration

    Oral administration

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.